News und Analysen
Agilent Announces Thought Leader Award to David R. Liu at the Broad Institute
Agilent Technologies Inc. (NYSE: A) today announced Dr. David R. Liu has been selected to receive a prestigious Agilent Thought Leader Award. A prominent researcher in the field of genome editing
Humana Foundation Donates $500,000 to Support Disaster Recovery in the Wake of Hurricane Ida
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $500,000 towards relief and recovery efforts for those impacted by Hurricane Ida in Louisiana
Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement
Agilent Technologies Inc. (NYSE: A) today announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
Pfizer Inc. (NYSE:PFE) today announced the initiation of RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease), a Phase 3 clinical trial evaluating the efficacy
Agilent to Present at Wells Fargo Virtual Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, Agilent President and CEO, and Bob McMahon, Agilent CFO, will participate in a “fireside chat” discussion at the Wells Fargo
Humana Foundation Donates $50,000 in Relief Efforts for Those Impacted by Flooding in Tennessee
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $50,000 in relief efforts for those impacted by recent flooding across Tennessee. This giving
Texas A&M University Mays Business School and Humana to Launch Fifth Annual Healthcare Analytics Case Competition
Mays Business School at Texas A&M University and leading health and well-being company Humana Inc. (NYSE: HUM) have announced the details of the 2021 Humana-Mays Healthcare Analytics Case
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase 3 study, met its co-primary and key
Pfizer Announces New Chief Business Innovation Officer
Pfizer Inc. (NYSE: PFE) today announced that Aamir Malik has joined the company as Executive Vice President and Chief Business Innovation Officer. Mr. Malik will be a member of Pfizer’s Executive
Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY® (COVID-19
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer
Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay has expanded its use in Europe. The assay is now CE-IVD marked for use as an aid in identifying
Pfizer to Acquire Trillium Therapeutics Inc.
Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (JIA) and
Researchers Develop COVID-19 Severity Screening Method Based on the Agilent Cary 630 FTIR Spectrometer
Agilent Technologies Inc. (NYSE: A) announces that researchers at the Indian Institute of Technology Bombay in India and the QIMR Berghofer Medical Research Institute in Australia have developed a
Agilent Reports Third-Quarter Fiscal Year 2021 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.59 billion for the third quarter ended July 31, 2021, an increase of 26% compared to the third quarter of 2020 and up 21% on a core(
Pfizer Prices $1.0 Billion Sustainability Bond
Pfizer Inc. (NYSE: PFE) today announced the pricing of a sustainability bond of $1,000,000,000 in aggregate principal amount of 1.750% senior notes due 2031.
The closing of the offering is
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or
U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TICOVAC™ (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in
Humana Highlights Commitment to Addressing Health Equity in 2020 Corporate Responsibility Report
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, today released its 2020 Corporate Social Responsibility (CSR) report. As outlined in the report, Humana details
Agilent Earns 2021 Great Place to Work Certification in the U.S.
Agilent Technologies Inc. (NYSE: A) today announced that it has been certified as a Great Place to Work in the U.S., a prestigious independent recognition based entirely on employee feedback about
Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata
Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease
Agilent Announces Target Enrichment Manufacturing Facility in China
Agilent Technologies Inc. (NYSE: A) today announced that is has established in-country manufacturing for its SureSelect portfolio at its facility in Hangzhou, China.
Agilent is a leading provider
Illumina to Webcast Upcoming Investor Conference
Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
-
UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021